These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma. Hadi M; Qutaiba B Allela O; Jabari M; Jasoor AM; Naderloo O; Yasamineh S; Gholizadeh O; Kalantari L Virol J; 2024 Jan; 21(1):17. PubMed ID: 38216938 [TBL] [Abstract][Full Text] [Related]
3. Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma. Wang YG; Huang PP; Zhang R; Ma BY; Zhou XM; Sun YF World J Gastroenterol; 2016 Jan; 22(1):326-37. PubMed ID: 26755879 [TBL] [Abstract][Full Text] [Related]
4. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. Peng D; Qian C; Sun Y; Barajas MA; Prieto J J Hepatol; 2000 Jun; 32(6):975-85. PubMed ID: 10898318 [TBL] [Abstract][Full Text] [Related]
5. Assessing the potential for AAV vector genotoxicity in a murine model. Li H; Malani N; Hamilton SR; Schlachterman A; Bussadori G; Edmonson SE; Shah R; Arruda VR; Mingozzi F; Wright JF; Bushman FD; High KA Blood; 2011 Mar; 117(12):3311-9. PubMed ID: 21106988 [TBL] [Abstract][Full Text] [Related]
6. Integration and the risk of liver cancer-Is there a real risk? Kasimsetty A; Sabatino DE J Viral Hepat; 2024 Apr; 31 Suppl 1():26-34. PubMed ID: 38606944 [TBL] [Abstract][Full Text] [Related]
7. AAV vector integration sites in mouse hepatocellular carcinoma. Donsante A; Miller DG; Li Y; Vogler C; Brunt EM; Russell DW; Sands MS Science; 2007 Jul; 317(5837):477. PubMed ID: 17656716 [TBL] [Abstract][Full Text] [Related]
8. AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage. Fang CC; Wu CF; Liao YJ; Huang SF; Chen M; Chen YA Sci Rep; 2018 Sep; 8(1):13802. PubMed ID: 30217986 [TBL] [Abstract][Full Text] [Related]
10. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Shi W; Arnold GS; Bartlett JS Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765 [TBL] [Abstract][Full Text] [Related]
12. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Müller OJ; Leuchs B; Pleger ST; Grimm D; Franz WM; Katus HA; Kleinschmidt JA Cardiovasc Res; 2006 Apr; 70(1):70-8. PubMed ID: 16448634 [TBL] [Abstract][Full Text] [Related]
13. Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. Dhungel B; Jayachandran A; Layton CJ; Steel JC Drug Deliv; 2017 Nov; 24(1):289-299. PubMed ID: 28165834 [TBL] [Abstract][Full Text] [Related]
14. Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver. Ohashi K; Nakai H; Couto LB; Kay MA Hum Gene Ther; 2005 Mar; 16(3):299-306. PubMed ID: 15812225 [TBL] [Abstract][Full Text] [Related]
15. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Su H; Chang JC; Xu SM; Kan YW Hum Gene Ther; 1996 Mar; 7(4):463-70. PubMed ID: 8800740 [TBL] [Abstract][Full Text] [Related]
16. Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Dalwadi DA; Torrens L; Abril-Fornaguera J; Pinyol R; Willoughby C; Posey J; Llovet JM; Lanciault C; Russell DW; Grompe M; Naugler WE Mol Ther; 2021 Feb; 29(2):680-690. PubMed ID: 33554867 [TBL] [Abstract][Full Text] [Related]
17. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Xu L; Daly T; Gao C; Flotte TR; Song S; Byrne BJ; Sands MS; Parker Ponder K Hum Gene Ther; 2001 Mar; 12(5):563-73. PubMed ID: 11268288 [TBL] [Abstract][Full Text] [Related]
18. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833 [TBL] [Abstract][Full Text] [Related]
19. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease. Janelidze S; Nordström U; Kügler S; Brundin P J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717 [TBL] [Abstract][Full Text] [Related]
20. Gene therapy methods in bone and joint disorders. Evaluation of the adeno-associated virus vector in experimental models of articular cartilage disorders, periprosthetic osteolysis and bone healing. Ulrich-Vinther M Acta Orthop Suppl; 2007 Apr; 78(325):1-64. PubMed ID: 17427340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]